View ValuationAlzChem Group 향후 성장Future 기준 점검 4/6AlzChem Group (는) 각각 연간 19.1% 및 11.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 27% 로 예상됩니다.핵심 정보19.1%이익 성장률18.97%EPS 성장률Chemicals 이익 성장39.3%매출 성장률11.2%향후 자기자본이익률27.00%애널리스트 커버리지Good마지막 업데이트07 May 2026최근 향후 성장 업데이트공시 • May 02AlzChem Group AG Confirms Earnings Guidance for the Fiscal Year 2025AlzChem Group AG confirmed earnings guidance for the fiscal year 2025. For the year, the Group sales are expected to grow by approximately 5% compared with the previous year.모든 업데이트 보기Recent updatesReported Earnings • May 05First quarter 2026 earnings released: EPS: €1.77 (vs €1.44 in 1Q 2025)First quarter 2026 results: EPS: €1.77 (up from €1.44 in 1Q 2025). Revenue: €156.0m (up 6.3% from 1Q 2025). Net income: €18.0m (up 23% from 1Q 2025). Profit margin: 12% (up from 9.9% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Apr 29Upcoming dividend of €2.10 per shareEligible shareholders must have bought the stock before 06 May 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (4.0%).공시 • Mar 25AlzChem Group AG, Annual General Meeting, May 05, 2026AlzChem Group AG, Annual General Meeting, May 05, 2026, at 10:00 W. Europe Standard Time.Buy Or Sell Opportunity • Mar 18Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to €175. The fair value is estimated to be €145, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.Declared Dividend • Mar 02Dividend increased to €2.10Dividend of €2.10 is 17% higher than last year. Ex-date: 6th May 2026 Payment date: 8th May 2026 Dividend yield will be 1.4%, which is lower than the industry average of 3.0%. Payout Ratios Payout ratio: 29%. Cash payout ratio: 46%.Reported Earnings • Mar 02Full year 2025 earnings released: EPS: €6.28 (vs €5.32 in FY 2024)Full year 2025 results: EPS: €6.28 (up from €5.32 in FY 2024). Revenue: €585.5m (up 3.9% from FY 2024). Net income: €63.5m (up 17% from FY 2024). Profit margin: 11% (up from 9.6% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth.공시 • Feb 28AlzChem Group AG announces Annual dividend, payable on May 08, 2026AlzChem Group AG announced Annual dividend of EUR 2.1000 per share payable on May 08, 2026, ex-date on May 06, 2026 and record date on May 07, 2026.New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €157, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 15x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 911% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €245 per share.공시 • Nov 06+ 3 more updatesAlzChem Group AG to Report Q3, 2026 Results on Oct 30, 2026AlzChem Group AG announced that they will report Q3, 2026 results on Oct 30, 2026Buy Or Sell Opportunity • Nov 03Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €157. The fair value is estimated to be €200, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.Reported Earnings • Nov 01Third quarter 2025 earnings released: EPS: €1.61 (vs €1.22 in 3Q 2024)Third quarter 2025 results: EPS: €1.61 (up from €1.22 in 3Q 2024). Revenue: €141.1m (up 6.3% from 3Q 2024). Net income: €16.3m (up 32% from 3Q 2024). Profit margin: 12% (up from 9.3% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 114% per year, which means it is tracking significantly ahead of earnings growth.공시 • Sep 24AlzChem Group AG to Report Q3, 2025 Results on Oct 30, 2025AlzChem Group AG announced that they will report Q3, 2025 results on Oct 30, 2025Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: €1.57 (vs €1.41 in 2Q 2024)Second quarter 2025 results: EPS: €1.57 (up from €1.41 in 2Q 2024). Revenue: €147.9m (up 4.2% from 2Q 2024). Net income: €15.8m (up 10% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.Buy Or Sell Opportunity • Jul 31Now 33% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to €151. The fair value is estimated to be €114, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €134, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 164% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €113 per share.Buy Or Sell Opportunity • Jun 26Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 41% to €137. The fair value is estimated to be €112, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.Buy Or Sell Opportunity • Jun 05Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 51% to €134. The fair value is estimated to be €111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.공시 • May 09AlzChem Group AG to Report First Half, 2025 Results on Jul 30, 2025AlzChem Group AG announced that they will report first half, 2025 results on Jul 30, 2025Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €125, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 9x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 541% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €113 per share.공시 • May 02AlzChem Group AG Confirms Earnings Guidance for the Fiscal Year 2025AlzChem Group AG confirmed earnings guidance for the fiscal year 2025. For the year, the Group sales are expected to grow by approximately 5% compared with the previous year.Reported Earnings • May 02First quarter 2025 earnings released: EPS: €1.44 (vs €1.20 in 1Q 2024)First quarter 2025 results: EPS: €1.44 (up from €1.20 in 1Q 2024). Revenue: €149.9m (down 1.1% from 1Q 2024). Net income: €14.6m (up 20% from 1Q 2024). Profit margin: 9.7% (up from 8.0% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • May 02Upcoming dividend of €1.80 per shareEligible shareholders must have bought the stock before 09 May 2025. Payment date: 13 May 2025. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (6.0%). Lower than average of industry peers (4.6%).Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €103, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 8x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 428% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €197 per share.공시 • Mar 29AlzChem Group AG, Annual General Meeting, May 08, 2025AlzChem Group AG, Annual General Meeting, May 08, 2025, at 10:00 W. Europe Standard Time.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €88.46, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 343% over the past three years.New Risk • Mar 04New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.8% average weekly change).Declared Dividend • Mar 03Dividend increased to €1.80Dividend of €1.80 is 50% higher than last year. Ex-date: 9th May 2025 Payment date: 13th May 2025 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (24% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 1.3% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 02Full year 2024 earnings released: EPS: €5.31 (vs €3.40 in FY 2023)Full year 2024 results: EPS: €5.31 (up from €3.40 in FY 2023). Revenue: €571.5m (up 4.7% from FY 2023). Net income: €54.1m (up 56% from FY 2023). Profit margin: 9.5% (up from 6.3% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.New Risk • Jan 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.공시 • Dec 06Alzchem Group Ag Appoints Martina Spitzer as A New Member of the Management Board, Effective from January 1, 2025AlzChem Group AG approved the appointment of Martina Spitzer as a new member of the Management Board for a term of three years from January 1, 2025 to December 31, 2027. In her new position as Chief Sales Officer (CSO), she will be responsible for the areas of Health & Nutrition (Creapure®), Fine Chemicals (Chemicals & Applications) and Sustainability (ESG). Ms. Spitzer’s appointment as CSO represents the next important step in the early succession planning for the Management Board. Ms. Spitzer is now already taking over two important business areas in sales, as Dr. Weichselbaumer will be in charge of the future project of setting up production in the USA. Ms. Spitzer has been with the Alzchem Group since 1999. In 2020, she was appointed Head of Alzchem’s entire chemical sales division, before she shifted her focus to strategic corporate development and ESG in 2022 after around 15 years in sales. In this role, she was instrumental in the introduction of the sustainability division, the optimization of central business processes and the implementation of forward-looking projects.공시 • Nov 27AlzChem Group AG to Report Q1, 2025 Results on Apr 30, 2025AlzChem Group AG announced that they will report Q1, 2025 results on Apr 30, 2025Reported Earnings • Nov 08Third quarter 2024 earnings released: EPS: €1.22 (vs €0.85 in 3Q 2023)Third quarter 2024 results: EPS: €1.22 (up from €0.85 in 3Q 2023). Revenue: €132.7m (up 7.0% from 3Q 2023). Net income: €12.4m (up 44% from 3Q 2023). Profit margin: 9.3% (up from 7.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom.공시 • Nov 08AlzChem Group AG to Report Fiscal Year 2024 Results on Feb 28, 2025AlzChem Group AG announced that they will report fiscal year 2024 results on Feb 28, 2025Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €51.80, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €37.39 per share.Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: €0.71 (vs €0.70 in 2Q 2023)Second quarter 2024 results: EPS: €0.71 (up from €0.70 in 2Q 2023). Revenue: €139.9m (up 5.2% from 2Q 2023). Net income: €14.4m (up 100% from 2Q 2023). Profit margin: 10% (up from 5.4% in 2Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 5.7% decline forecast for the Chemicals industry in the United Kingdom.공시 • Aug 02AlzChem Group AG to Report Q3, 2024 Results on Nov 07, 2024AlzChem Group AG announced that they will report Q3, 2024 results on Nov 07, 2024공시 • May 09AlzChem Group AG to Report First Half, 2024 Results on Aug 01, 2024AlzChem Group AG announced that they will report first half, 2024 results on Aug 01, 2024Reported Earnings • May 01First quarter 2024 earnings released: EPS: €1.20 (vs €0.76 in 1Q 2023)First quarter 2024 results: EPS: €1.20 (up from €0.76 in 1Q 2023). Revenue: €153.6m (up 1.4% from 1Q 2023). Net income: €12.2m (up 59% from 1Q 2023). Profit margin: 7.9% (up from 5.1% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom.Declared Dividend • Mar 28Dividend increased to €1.20Dividend of €1.20 is 14% higher than last year. Ex-date: 8th May 2024 Payment date: 10th May 2024 Dividend yield will be 3.6%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 1.5% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Mar 05Full year 2023 earnings released: EPS: €3.40 (vs €2.97 in FY 2022)Full year 2023 results: EPS: €3.40 (up from €2.97 in FY 2022). Revenue: €554.5m (flat on FY 2022). Net income: €34.6m (up 15% from FY 2022). Profit margin: 6.2% (up from 5.5% in FY 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.공시 • Nov 30AlzChem Group AG to Report Q1, 2024 Results on Apr 30, 2024AlzChem Group AG announced that they will report Q1, 2024 results on Apr 30, 2024공시 • Oct 27AlzChem Group AG to Report Fiscal Year 2023 Results on Mar 01, 2024AlzChem Group AG announced that they will report fiscal year 2023 results on Mar 01, 2024공시 • Sep 19AlzChem Group AG to Report Q3, 2023 Results on Oct 26, 2023AlzChem Group AG announced that they will report Q3, 2023 results on Oct 26, 2023New Risk • Aug 05New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 44% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks High level of debt (44% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Reported Earnings • Aug 04Second quarter 2023 earnings released: EPS: €0.71 (vs €0.95 in 2Q 2022)Second quarter 2023 results: EPS: €0.71 (down from €0.95 in 2Q 2022). Revenue: €128.5m (down 14% from 2Q 2022). Net income: €7.20m (down 25% from 2Q 2022). Profit margin: 5.6% (down from 6.5% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom.공시 • May 05AlzChem Group AG to Report First Half, 2023 Results on Aug 03, 2023AlzChem Group AG announced that they will report first half, 2023 results on Aug 03, 2023Reported Earnings • May 05First quarter 2023 earnings released: EPS: €0.76 (vs €0.76 in 1Q 2022)First quarter 2023 results: EPS: €0.76 (down from €0.76 in 1Q 2022). Revenue: €156.0m (up 19% from 1Q 2022). Net income: €7.67m (flat on 1Q 2022). Profit margin: 4.9% (down from 5.9% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Reported Earnings • Mar 02Full year 2022 earnings released: EPS: €2.96 (vs €2.72 in FY 2021)Full year 2022 results: EPS: €2.96 (up from €2.72 in FY 2021). Revenue: €566.4m (up 32% from FY 2021). Net income: €30.1m (up 8.9% from FY 2021). Profit margin: 5.3% (down from 6.4% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공시 • Dec 09AlzChem Group AG, Annual General Meeting, May 11, 2023AlzChem Group AG, Annual General Meeting, May 11, 2023, at 10:00 Central European Standard Time.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: €0.59 (vs €0.46 in 3Q 2021)Third quarter 2022 results: EPS: €0.59 (up from €0.46 in 3Q 2021). Revenue: €145.1m (up 48% from 3Q 2021). Net income: €5.93m (up 27% from 3Q 2021). Profit margin: 4.1% (down from 4.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 8.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.공시 • Oct 27AlzChem Group AG to Report Fiscal Year 2022 Final Results on Feb 28, 2023AlzChem Group AG announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Feb 28, 2023Reported Earnings • May 12First quarter 2022 earnings released: EPS: €0.76 (vs €0.78 in 1Q 2021)First quarter 2022 results: EPS: €0.76 (down from €0.78 in 1Q 2021). Revenue: €133.5m (up 23% from 1Q 2021). Net income: €7.70m (down 2.4% from 1Q 2021). Profit margin: 5.8% (down from 7.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11% compared to a 18% decline forecast for the industry in the United Kingdom.Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS €0.46 (vs €0.37 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €98.1m (up 17% from 3Q 2020). Net income: €4.69m (up 25% from 3Q 2020). Profit margin: 4.8% (up from 4.5% in 3Q 2020). The increase in margin was driven by higher revenue.Reported Earnings • May 07First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €108.3m (up 13% from 1Q 2020). Net income: €7.89m (up 80% from 1Q 2020). Profit margin: 7.3% (up from 4.6% in 1Q 2020). The increase in margin was driven by higher revenue.Upcoming Dividend • May 07Upcoming dividend of €0.77 per shareEligible shareholders must have bought the stock before 13 May 2021. Payment date: 18 May 2021. Trailing yield: 3.1%. Lower than top quartile of British dividend payers (4.1%). Higher than average of industry peers (1.6%).이익 및 매출 성장 예측LSE:0ACT - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202881510894118512/31/202770587-1489612/31/202660667114563/31/2026581674125N/A12/31/20255756339137N/A9/30/202557662102146N/A6/30/20255685869113N/A3/31/20255595672121N/A12/31/20245635462105N/A9/30/20245645082103N/A6/30/2024555467697N/A3/31/2024546397396N/A12/31/2023546355273N/A9/30/2023533302555N/A6/30/2023554282453N/A3/31/202357030-1512N/A12/31/202255030-33-4N/A9/30/202253429-254N/A6/30/202248728-280N/A3/31/202245427329N/A12/31/2021429281443N/A9/30/2021420271140N/A6/30/2021406263463N/A3/31/2021397231448N/A12/31/2020386202049N/A9/30/2020370161052N/A6/30/2020389171153N/A3/31/2020387172054N/A12/31/201938518N/A44N/A9/30/201938919N/A42N/A6/30/201938018N/A22N/A3/31/201938020N/A33N/A12/31/201838323N/A35N/A9/30/201838022N/A24N/A6/30/201839832N/A31N/A3/31/201836421N/A23N/A12/31/201736120N/A31N/A9/30/201735622N/A31N/A12/31/201633315N/A33N/A9/30/201633112N/A39N/A12/31/201532915N/A30N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 0ACT 의 연간 예상 수익 증가율(19.1%)이 saving rate(3.4%)보다 높습니다.수익 vs 시장: 0ACT 의 연간 수익(19.1%)이 UK 시장(11.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 0ACT 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 0ACT 의 수익(연간 11.2%)이 UK 시장(연간 4.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 0ACT 의 수익(연간 11.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 0ACT의 자본 수익률은 3년 후 27%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/25 18:28종가2026/05/25 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스AlzChem Group AG는 8명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Konstantin WiechertBaader Helvea Equity ResearchVolker BosseBaader Helvea Equity ResearchGerhard OrgonasBerenberg5명의 분석가 더 보기
공시 • May 02AlzChem Group AG Confirms Earnings Guidance for the Fiscal Year 2025AlzChem Group AG confirmed earnings guidance for the fiscal year 2025. For the year, the Group sales are expected to grow by approximately 5% compared with the previous year.
Reported Earnings • May 05First quarter 2026 earnings released: EPS: €1.77 (vs €1.44 in 1Q 2025)First quarter 2026 results: EPS: €1.77 (up from €1.44 in 1Q 2025). Revenue: €156.0m (up 6.3% from 1Q 2025). Net income: €18.0m (up 23% from 1Q 2025). Profit margin: 12% (up from 9.9% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 104% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Apr 29Upcoming dividend of €2.10 per shareEligible shareholders must have bought the stock before 06 May 2026. Payment date: 08 May 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (4.0%).
공시 • Mar 25AlzChem Group AG, Annual General Meeting, May 05, 2026AlzChem Group AG, Annual General Meeting, May 05, 2026, at 10:00 W. Europe Standard Time.
Buy Or Sell Opportunity • Mar 18Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to €175. The fair value is estimated to be €145, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings are also forecast to grow by 19% per annum over the same time period.
Declared Dividend • Mar 02Dividend increased to €2.10Dividend of €2.10 is 17% higher than last year. Ex-date: 6th May 2026 Payment date: 8th May 2026 Dividend yield will be 1.4%, which is lower than the industry average of 3.0%. Payout Ratios Payout ratio: 29%. Cash payout ratio: 46%.
Reported Earnings • Mar 02Full year 2025 earnings released: EPS: €6.28 (vs €5.32 in FY 2024)Full year 2025 results: EPS: €6.28 (up from €5.32 in FY 2024). Revenue: €585.5m (up 3.9% from FY 2024). Net income: €63.5m (up 17% from FY 2024). Profit margin: 11% (up from 9.6% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 10% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 101% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Feb 28AlzChem Group AG announces Annual dividend, payable on May 08, 2026AlzChem Group AG announced Annual dividend of EUR 2.1000 per share payable on May 08, 2026, ex-date on May 06, 2026 and record date on May 07, 2026.
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment improves as stock rises 23%After last week's 23% share price gain to €157, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 15x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 911% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €245 per share.
공시 • Nov 06+ 3 more updatesAlzChem Group AG to Report Q3, 2026 Results on Oct 30, 2026AlzChem Group AG announced that they will report Q3, 2026 results on Oct 30, 2026
Buy Or Sell Opportunity • Nov 03Now 22% undervaluedThe stock has been flat over the last 90 days, currently trading at €157. The fair value is estimated to be €200, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 30%. For the next 3 years, revenue is forecast to grow by 8.8% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
Reported Earnings • Nov 01Third quarter 2025 earnings released: EPS: €1.61 (vs €1.22 in 3Q 2024)Third quarter 2025 results: EPS: €1.61 (up from €1.22 in 3Q 2024). Revenue: €141.1m (up 6.3% from 3Q 2024). Net income: €16.3m (up 32% from 3Q 2024). Profit margin: 12% (up from 9.3% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has increased by 114% per year, which means it is tracking significantly ahead of earnings growth.
공시 • Sep 24AlzChem Group AG to Report Q3, 2025 Results on Oct 30, 2025AlzChem Group AG announced that they will report Q3, 2025 results on Oct 30, 2025
Reported Earnings • Aug 01Second quarter 2025 earnings released: EPS: €1.57 (vs €1.41 in 2Q 2024)Second quarter 2025 results: EPS: €1.57 (up from €1.41 in 2Q 2024). Revenue: €147.9m (up 4.2% from 2Q 2024). Net income: €15.8m (up 10% from 2Q 2024). Profit margin: 11% (in line with 2Q 2024). Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.
Buy Or Sell Opportunity • Jul 31Now 33% overvalued after recent price riseOver the last 90 days, the stock has risen 20% to €151. The fair value is estimated to be €114, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.5% per annum. Earnings are also forecast to grow by 17% per annum over the same time period.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €134, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 164% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €113 per share.
Buy Or Sell Opportunity • Jun 26Now 23% overvalued after recent price riseOver the last 90 days, the stock has risen 41% to €137. The fair value is estimated to be €112, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
Buy Or Sell Opportunity • Jun 05Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 51% to €134. The fair value is estimated to be €111, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 27%. For the next 3 years, revenue is forecast to grow by 8.4% per annum. Earnings are also forecast to grow by 16% per annum over the same time period.
공시 • May 09AlzChem Group AG to Report First Half, 2025 Results on Jul 30, 2025AlzChem Group AG announced that they will report first half, 2025 results on Jul 30, 2025
Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €125, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 9x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 541% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €113 per share.
공시 • May 02AlzChem Group AG Confirms Earnings Guidance for the Fiscal Year 2025AlzChem Group AG confirmed earnings guidance for the fiscal year 2025. For the year, the Group sales are expected to grow by approximately 5% compared with the previous year.
Reported Earnings • May 02First quarter 2025 earnings released: EPS: €1.44 (vs €1.20 in 1Q 2024)First quarter 2025 results: EPS: €1.44 (up from €1.20 in 1Q 2024). Revenue: €149.9m (down 1.1% from 1Q 2024). Net income: €14.6m (up 20% from 1Q 2024). Profit margin: 9.7% (up from 8.0% in 1Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 4.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has increased by 70% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • May 02Upcoming dividend of €1.80 per shareEligible shareholders must have bought the stock before 09 May 2025. Payment date: 13 May 2025. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of British dividend payers (6.0%). Lower than average of industry peers (4.6%).
Valuation Update With 7 Day Price Move • Apr 14Investor sentiment improves as stock rises 19%After last week's 19% share price gain to €103, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 8x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 428% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €197 per share.
공시 • Mar 29AlzChem Group AG, Annual General Meeting, May 08, 2025AlzChem Group AG, Annual General Meeting, May 08, 2025, at 10:00 W. Europe Standard Time.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €88.46, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 10x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 343% over the past three years.
New Risk • Mar 04New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.2% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.8% average weekly change).
Declared Dividend • Mar 03Dividend increased to €1.80Dividend of €1.80 is 50% higher than last year. Ex-date: 9th May 2025 Payment date: 13th May 2025 Dividend yield will be 2.3%, which is lower than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (24% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 1.3% per year over the past 7 years. However, payments have been volatile during that time. EPS is expected to grow by 41% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 02Full year 2024 earnings released: EPS: €5.31 (vs €3.40 in FY 2023)Full year 2024 results: EPS: €5.31 (up from €3.40 in FY 2023). Revenue: €571.5m (up 4.7% from FY 2023). Net income: €54.1m (up 56% from FY 2023). Profit margin: 9.5% (up from 6.3% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 3.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 50% per year, which means it is tracking significantly ahead of earnings growth.
New Risk • Jan 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
공시 • Dec 06Alzchem Group Ag Appoints Martina Spitzer as A New Member of the Management Board, Effective from January 1, 2025AlzChem Group AG approved the appointment of Martina Spitzer as a new member of the Management Board for a term of three years from January 1, 2025 to December 31, 2027. In her new position as Chief Sales Officer (CSO), she will be responsible for the areas of Health & Nutrition (Creapure®), Fine Chemicals (Chemicals & Applications) and Sustainability (ESG). Ms. Spitzer’s appointment as CSO represents the next important step in the early succession planning for the Management Board. Ms. Spitzer is now already taking over two important business areas in sales, as Dr. Weichselbaumer will be in charge of the future project of setting up production in the USA. Ms. Spitzer has been with the Alzchem Group since 1999. In 2020, she was appointed Head of Alzchem’s entire chemical sales division, before she shifted her focus to strategic corporate development and ESG in 2022 after around 15 years in sales. In this role, she was instrumental in the introduction of the sustainability division, the optimization of central business processes and the implementation of forward-looking projects.
공시 • Nov 27AlzChem Group AG to Report Q1, 2025 Results on Apr 30, 2025AlzChem Group AG announced that they will report Q1, 2025 results on Apr 30, 2025
Reported Earnings • Nov 08Third quarter 2024 earnings released: EPS: €1.22 (vs €0.85 in 3Q 2023)Third quarter 2024 results: EPS: €1.22 (up from €0.85 in 3Q 2023). Revenue: €132.7m (up 7.0% from 3Q 2023). Net income: €12.4m (up 44% from 3Q 2023). Profit margin: 9.3% (up from 7.0% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 6.6% decline forecast for the Chemicals industry in the United Kingdom.
공시 • Nov 08AlzChem Group AG to Report Fiscal Year 2024 Results on Feb 28, 2025AlzChem Group AG announced that they will report fiscal year 2024 results on Feb 28, 2025
Valuation Update With 7 Day Price Move • Oct 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €51.80, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 13x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 136% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €37.39 per share.
Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: €0.71 (vs €0.70 in 2Q 2023)Second quarter 2024 results: EPS: €0.71 (up from €0.70 in 2Q 2023). Revenue: €139.9m (up 5.2% from 2Q 2023). Net income: €14.4m (up 100% from 2Q 2023). Profit margin: 10% (up from 5.4% in 2Q 2023). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 5.7% decline forecast for the Chemicals industry in the United Kingdom.
공시 • Aug 02AlzChem Group AG to Report Q3, 2024 Results on Nov 07, 2024AlzChem Group AG announced that they will report Q3, 2024 results on Nov 07, 2024
공시 • May 09AlzChem Group AG to Report First Half, 2024 Results on Aug 01, 2024AlzChem Group AG announced that they will report first half, 2024 results on Aug 01, 2024
Reported Earnings • May 01First quarter 2024 earnings released: EPS: €1.20 (vs €0.76 in 1Q 2023)First quarter 2024 results: EPS: €1.20 (up from €0.76 in 1Q 2023). Revenue: €153.6m (up 1.4% from 1Q 2023). Net income: €12.2m (up 59% from 1Q 2023). Profit margin: 7.9% (up from 5.1% in 1Q 2023). The increase in margin was primarily driven by lower expenses. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% decline forecast for the Chemicals industry in the United Kingdom.
Declared Dividend • Mar 28Dividend increased to €1.20Dividend of €1.20 is 14% higher than last year. Ex-date: 8th May 2024 Payment date: 10th May 2024 Dividend yield will be 3.6%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (23% cash payout ratio). The dividend has increased by an average of 1.5% per year over the past 6 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Mar 05Full year 2023 earnings released: EPS: €3.40 (vs €2.97 in FY 2022)Full year 2023 results: EPS: €3.40 (up from €2.97 in FY 2022). Revenue: €554.5m (flat on FY 2022). Net income: €34.6m (up 15% from FY 2022). Profit margin: 6.2% (up from 5.5% in FY 2022). Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.3% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
공시 • Nov 30AlzChem Group AG to Report Q1, 2024 Results on Apr 30, 2024AlzChem Group AG announced that they will report Q1, 2024 results on Apr 30, 2024
공시 • Oct 27AlzChem Group AG to Report Fiscal Year 2023 Results on Mar 01, 2024AlzChem Group AG announced that they will report fiscal year 2023 results on Mar 01, 2024
공시 • Sep 19AlzChem Group AG to Report Q3, 2023 Results on Oct 26, 2023AlzChem Group AG announced that they will report Q3, 2023 results on Oct 26, 2023
New Risk • Aug 05New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 44% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risks High level of debt (44% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Reported Earnings • Aug 04Second quarter 2023 earnings released: EPS: €0.71 (vs €0.95 in 2Q 2022)Second quarter 2023 results: EPS: €0.71 (down from €0.95 in 2Q 2022). Revenue: €128.5m (down 14% from 2Q 2022). Net income: €7.20m (down 25% from 2Q 2022). Profit margin: 5.6% (down from 6.5% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom.
공시 • May 05AlzChem Group AG to Report First Half, 2023 Results on Aug 03, 2023AlzChem Group AG announced that they will report first half, 2023 results on Aug 03, 2023
Reported Earnings • May 05First quarter 2023 earnings released: EPS: €0.76 (vs €0.76 in 1Q 2022)First quarter 2023 results: EPS: €0.76 (down from €0.76 in 1Q 2022). Revenue: €156.0m (up 19% from 1Q 2022). Net income: €7.67m (flat on 1Q 2022). Profit margin: 4.9% (down from 5.9% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Mar 02Full year 2022 earnings released: EPS: €2.96 (vs €2.72 in FY 2021)Full year 2022 results: EPS: €2.96 (up from €2.72 in FY 2021). Revenue: €566.4m (up 32% from FY 2021). Net income: €30.1m (up 8.9% from FY 2021). Profit margin: 5.3% (down from 6.4% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공시 • Dec 09AlzChem Group AG, Annual General Meeting, May 11, 2023AlzChem Group AG, Annual General Meeting, May 11, 2023, at 10:00 Central European Standard Time.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: €0.59 (vs €0.46 in 3Q 2021)Third quarter 2022 results: EPS: €0.59 (up from €0.46 in 3Q 2021). Revenue: €145.1m (up 48% from 3Q 2021). Net income: €5.93m (up 27% from 3Q 2021). Profit margin: 4.1% (down from 4.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.1% p.a. on average during the next 3 years, compared to a 8.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
공시 • Oct 27AlzChem Group AG to Report Fiscal Year 2022 Final Results on Feb 28, 2023AlzChem Group AG announced that they will report fiscal year 2022 final results at 9:00 AM, Central European Standard Time on Feb 28, 2023
Reported Earnings • May 12First quarter 2022 earnings released: EPS: €0.76 (vs €0.78 in 1Q 2021)First quarter 2022 results: EPS: €0.76 (down from €0.78 in 1Q 2021). Revenue: €133.5m (up 23% from 1Q 2021). Net income: €7.70m (down 2.4% from 1Q 2021). Profit margin: 5.8% (down from 7.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 11% compared to a 18% decline forecast for the industry in the United Kingdom.
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS €0.46 (vs €0.37 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €98.1m (up 17% from 3Q 2020). Net income: €4.69m (up 25% from 3Q 2020). Profit margin: 4.8% (up from 4.5% in 3Q 2020). The increase in margin was driven by higher revenue.
Reported Earnings • May 07First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €108.3m (up 13% from 1Q 2020). Net income: €7.89m (up 80% from 1Q 2020). Profit margin: 7.3% (up from 4.6% in 1Q 2020). The increase in margin was driven by higher revenue.
Upcoming Dividend • May 07Upcoming dividend of €0.77 per shareEligible shareholders must have bought the stock before 13 May 2021. Payment date: 18 May 2021. Trailing yield: 3.1%. Lower than top quartile of British dividend payers (4.1%). Higher than average of industry peers (1.6%).